Neumora Therapeutics, Inc.

As of May 27, 2025, the market trend is mildly bearish, indicated by mixed signals from key indicators like MACD, Bollinger Bands, and moving averages, suggesting a cautious outlook with prevailing bearish tendencies.

Neumora Therapeutics, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $68 million and a market cap of $128.27 million. Key financial metrics include a negative P/E ratio, a debt-to-equity ratio of -1.09, and a return on equity of -113%.

As of Jun 18, Neumora Therapeutics, Inc. has a market capitalization of 128.27 million, with net sales of 0.00 million and a net profit of -258.06 million over the latest four quarters. The company reported shareholder's funds of 287.06 million and total assets of 316.97 million as of Dec 24.